A
Ascendis Pharma A/S (ASND)
NMS – Real Time Price. Currency in USD
260.75
-0.83 (-0.32%)
At close: Jun 26, 2026, 4:00 PM EDT
261.00
+0.25 (0.10%)
After-hours: Jun 26, 2026, 4:48 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
260.75
-0.83 (-0.32%)
At close: Jun 26, 2026, 4:00 PM EDT
261.00
+0.25 (0.10%)
After-hours: Jun 26, 2026, 4:48 PM EDT
No Data
There are no news for this stock.
Total debt $1.0B significantly exceeds cash reserves ($660.0M), raising financial stability concerns
Total current assets $1.3B are just enough to cover Total current liabilities $1.3B, indicating tight liquidity
Debt-to-equity ratio (1.8) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (0.4x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$18.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.00 | 6.05 | 6.0 | |
| Quick ratio | 0.72 | 5.63 | 4.0 | |
| Debt to Equity | 1.84 | 0.30 | 3.0 | |
| Debt to Assets | 0.45 | 1.04 | 5.0 | |
| Interest coverage | 0.37 | -16.91 | 2.0 | |
| Weighted average score | 4.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 54M | 288M | 393M | 813M | 1.01B |
| Gross Profit | 26M | 225M | 333M | 691M | 878M |
| Operating Income | -590M | -492M | -302M | -154M | -7M |
| Net Income | -613M | -520M | -409M | -257M | 582M |
| EBITDA | -572M | -472M | -282M | -134M | 14M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 99.77 | 277.99 | 10 |
| Next quarter | 58.95 | 210.56 | 10 |
| Current year | 78.93 | 444.78 | 10 |
| Next year | 45.39 | -29.45 | 5.5 |
| Weighted average score | 8.9 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 0.15 | 1984.81 | 1843.84 | -122.13 | 5.8 |
| Y/Y | 171.53 | 839.31 | 759.02 | -14.24 | 7.8 |
| 3y average | 193.06 | 24.53 | 26.09 | 51.72 | 10 |
| 5y average | 216.04 | 8.69 | 11.97 | 19.07 | 8.0 |
| Weighted average score | 7.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Narrow | 3.0 |
| Intangible assets | Wide | 8.0 |
| Switching costs | Medium | 6.0 |
| Network effect | None | 1.0 |
| Economies of scale | Narrow | 4.0 |
| Weighted average score | 4.4 | |